[1] Speranza, L. et al. (2021) Dopamine: The neuromodulator of long-term synaptic plasticity, reward and movement control. Cells. 10: 735.
[2] Jeffs, Q. L. et al. (2023) Potential neural substrates underlying circadian and olfactory disruptions in preclinical Alzheimer's disease. Front. Neurosci. 17:1295998.
[3] Surmeier, D. J. et al. (2009) Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection. Curr. Opin. Neurobiol. 19: 621–628.
[4] Lammel, S. et al. (2014) Reward and aversion in a heterogeneous midbrain dopamine system. Neuropharmacology. 76: 351–359.
[5] Zhou, Z. D. et al. (2023) Role of dopamine in the pathophysiology of Parkinson’s disease. Transl. Neurodegener. 12: 44.
[6] Rommelfanger, K. S. and Weinshenker, D. (2007) Norepinephrine: The redheaded stepchild of Parkinson's disease. Biochem. Pharmacol. 74: 177–190.
[7] Daubner, S. C. et al. (2011) Tyrosine hydroxylase and regulation of dopamine synthesis. Arch. Biochem. Biophys. 508: 1–12.
[8] Klein M.O. et al. (2019) Dopamine: Functions, signaling, and association with neurological diseases. Cell. Mol. Neurobiol. 39: 31-59.